Biotech Startups

ClinChoice operates a network of investigator sites that participate in clinical studies to support drug and device development. The platform connects research sites with clinical trial opportunities and commercialization support.

3 investors

Caidya is a contract research organization (CRO) that provides scientific, medical, and operational support for clinical development and cross-border clinical trials. It focuses on managing complex trials and delivering clinical data to support decision-making for drug developers.

3 investors

CoapTech makes the PUMA-G System, an FDA-cleared ultrasound-based device for bedside feeding tube (gastrostomy) placement, used in ICUs, step-down units, IR suites, and long-term acute care hospitals. The system aims to reduce hospital costs, procedure risks, and ICU/hospital length of stay compared to conventional PEG or PRG procedures.

3 investors

Codetta Bio develops multiplex biomarker detection technology that combines digital PCR, real-time PCR, and immunoPCR with microbead-based target capture to simultaneously measure proteins, DNA, and RNA from a single sample. Its tools serve multi-omics research and life sciences applications.

3 investors

Colorifix uses engineered microorganisms to produce, deposit, and fix dyes on textiles through a biological fermentation process, aiming to reduce the environmental impact of textile dyeing. It develops and manufactures bioreactors and fermentation media for textile industry customers.

3 investors

3 investors

Connect Biopharm develops next-generation therapeutics for inflammatory diseases. The company focuses on drug development aimed at treating patients with inflammatory conditions.

3 investors

Context Therapeutics develops clinical-stage T cell engaging bispecific antibody therapies for the treatment of solid tumors. Its pipeline targets antigens such as Claudin 6, mesothelin, and Nectin-4 to direct the immune system against difficult-to-treat cancers.

3 investors

Contineum is a biopharmaceutical company developing small molecule drug candidates to treat inflammatory and fibrotic diseases by modulating critical disease pathways. The company is advancing multiple candidates into clinical trials, with a focus on diseases of high unmet medical need.

3 investors

Convelo Therapeutics develops remyelination-enhancing therapies that target the central nervous system's myelination pathway to repair nerve damage in people with multiple sclerosis. The company operates a drug discovery platform focused on neurological disorders and originated from research at Case Western Reserve University.

3 investors

Converge Bio develops generative AI models trained on DNA, RNA, and protein sequences to support drug discovery and development for biotech and pharmaceutical companies. The company provides AI solutions for target discovery, antibody design, protein manufacturing optimization, and biomarker discovery.

3 investors

Coral Genomics develops clinical laboratory tests that combine molecular, functional, and clinical data to predict the most effective treatments for patients with autoimmune diseases. The company also works on addressing a subpopulation of patients who do not respond to current autoimmune therapies.

3 investors

Corcept develops cortisol modulators — molecules that regulate cortisol activity at the glucocorticoid receptor — to treat serious diseases across endocrinology, oncology, metabolism, and neurology. Its FDA-approved drug Korlym (mifepristone) treats hypercortisolism (Cushing syndrome), and the company has over 30 ongoing studies and more than 1,000 discovered proprietary cortisol modulators.

3 investors

CoreMap develops medical technology that lets physicians visualize atrial fibrillation (AF), an irregular heart arrhythmia, to inform better treatment options for patients. It targets cardiac electrophysiology and diagnostics.

3 investors

Cornerstone provides expert-guided AI software that organizes, standardizes, and harmonizes life science data from clinical trials, labs, and EHRs to produce analysis-ready datasets. It serves pharma companies and healthcare data providers looking to reduce data preparation timelines while maintaining auditability.

3 investors

Corporis Medical develops medical devices for surgical and diagnostic applications, focusing on innovations like perfusion measurement systems and clinical validation.

3 investors

Acquired by Novo Nordisk in 2020.

3 investors

CorWave produces a ventricular assist pump for advanced heart failure patients, delivering pulsatile flow to provide mechanical cardiac support for transplant candidates, non-transplant-eligible patients, and recovery cases.

3 investors

Cresilon develops plant-based flowable hemostatic gel technology that controls bleeding within seconds without manual pressure, with products for veterinary care (VETIGEL) and human trauma (TRAUMAGEL). Its customers include EMS agencies, trauma hospitals, military, law enforcement, and veterinary practices.

3 investors

CRISPR QC develops the CRISPR Analytics Platform, a graphene-based biosensor system that provides real-time quantitative kinetic measurements of RNP formation, DNA target binding, and CRISPR-Cas cleavage activity. It serves gene-editing discovery, development, and manufacturing teams to pre-screen gRNA efficiency and de-risk experiments before costly downstream sequencing and screening.

3 investors

Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies. The company creates next-generation T-cell engagers incorporating its proprietary T-Bolt™ molecules to enhance therapeutic potency and manufacturability.

3 investors

Cultivated develops Cosaic Neo, a multipurpose food ingredient that combines texture, nutrition, and clean-label properties for beverage and food manufacturers. The product addresses the compromise between taste, nutritional performance, and ingredient transparency in food formulation.

3 investors

Curie Co develops sustainable ingredients based on natural processes for use in consumer goods including personal care, textiles, and food products. The company focuses on creating planet-friendly formulations that maintain performance without environmental compromise.

3 investors

Cyfuse Bio develops 3D cell-based tissue and organ products created from cells alone, without artificial materials, for transplantation to restore original tissue and organ function in regenerative medicine applications.

3 investors